178 related articles for article (PubMed ID: 25601427)
21. HDL-cholesterol in coronary artery disease risk: function or structure?
Pérez-Méndez Ó; Pacheco HG; Martínez-Sánchez C; Franco M
Clin Chim Acta; 2014 Feb; 429():111-22. PubMed ID: 24333390
[TBL] [Abstract][Full Text] [Related]
22. Inflammation alters HDL composition and function: implications for HDL-raising therapies.
Marsche G; Saemann MD; Heinemann A; Holzer M
Pharmacol Ther; 2013 Mar; 137(3):341-51. PubMed ID: 23246719
[TBL] [Abstract][Full Text] [Related]
23. Effects of oral contraceptives on lipid metabolism.
Krauss RM
J Reprod Med; 1986 Jun; 31(6 Suppl):549-50. PubMed ID: 3723487
[TBL] [Abstract][Full Text] [Related]
24. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
25. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
Santos-Gallego CG; Ibanez B; Badimon JJ
Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
[TBL] [Abstract][Full Text] [Related]
26. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
Otocka-Kmiecik A; Mikhailidis DP; Nicholls SJ; Davidson M; Rysz J; Banach M
Prog Lipid Res; 2012 Oct; 51(4):314-24. PubMed ID: 22609245
[TBL] [Abstract][Full Text] [Related]
27. miRNAs and High-Density Lipoprotein metabolism.
Baldán Á; de Aguiar Vallim TQ
Biochim Biophys Acta; 2016 Dec; 1861(12 Pt B):2053-2061. PubMed ID: 26869447
[TBL] [Abstract][Full Text] [Related]
28. Novel therapies focused on the high-density lipoprotein particle.
van Capelleveen JC; Brewer HB; Kastelein JJ; Hovingh GK
Circ Res; 2014 Jan; 114(1):193-204. PubMed ID: 24385512
[TBL] [Abstract][Full Text] [Related]
29. High-density lipoprotein cholesterol raising: does it matter?
Schofield JD; France M; Ammori B; Liu Y; Soran H
Curr Opin Cardiol; 2013 Jul; 28(4):464-74. PubMed ID: 23736820
[TBL] [Abstract][Full Text] [Related]
30. HDL and cardiovascular disease.
Rader DJ; Hovingh GK
Lancet; 2014 Aug; 384(9943):618-625. PubMed ID: 25131981
[TBL] [Abstract][Full Text] [Related]
31. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
32. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
34. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
35. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264
[TBL] [Abstract][Full Text] [Related]
36. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
38. High-density lipoprotein subfractions: current views and clinical practice applications.
Martin SS; Jones SR; Toth PP
Trends Endocrinol Metab; 2014 Jul; 25(7):329-36. PubMed ID: 24931711
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms regulating hepatic SR-BI expression and their impact on HDL metabolism.
Leiva A; Verdejo H; Benítez ML; Martínez A; Busso D; Rigotti A
Atherosclerosis; 2011 Aug; 217(2):299-307. PubMed ID: 21741044
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
